Ophidion, Inc. is an early-stage central nervous system (CNS) biopharmaceutical company. Our foundational science has enabled us to create a proprietary carrier technology to enhance brain penetration of drugs and large molecules that would otherwise not enter the brain when administered systemically. From this proprietary platform technology, we have created a pipeline of therapeutics for the treatment of CNS disorders. A major focus of our pipeline is the delivery of gene-silencing siRNA to the brain to treat Huntington’s disease and cognitive disorders, along with treatments for other indications (e.g. pain, anxiety). We are currently a preclinical-stage company, but expect to soon be clinical-stage with two IND filings within the next 24 months.
Contact us at [email protected].